Why a Sudoku-solving program looks smart: Recursion, backtracking, and the idea of 'trying from the most likely failure points'

I was thinking about a program to solve Sudoku.You fill a 9x9 grid with numbers from 1 to 9. The same number must not be ...

Is Recursion Pharmaceuticals (RXRX) Undervalued Following Sanofi’s First Option Milestone?

Recursion Pharmaceuticals (RXRX) just moved onto many investors’ radar after Sanofi optioned the first development candidate ...

Recursion Pharmaceuticals (RXRX) Reached A $10 Million Immunology Milestone

Recursion Pharmaceuticals (NasdaqGS:RXRX) said Sanofi has exercised its option on the first immunology candidate in their ...
Stocktwits on MSN

RXRX stock heads for its best day in over a year – what's driving the rally today?

The update comes alongside a $200 million stock offering that Recursion expects will fund operations into 2029. If the current levels hold, RXRX stock would record its biggest single-day gains in ...
manilatimes

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated ...
Nasdaq

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...
MarketScreener

Recursion Pharmaceuticals, Inc. Announces Sanofi Options Potential First-In-Class Immunology Development Candidate From Their Collaboration

Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...